UK Antibiotics Play Novacta Wins £13.1 million, mostly from Celtic Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Funds should allow Novacta Biosystems to take three peptide-based ‘lantibiotics' programs through to proof-of-efficacy and secure a licensing deal
You may also be interested in...
Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline
Antibiotic resistance has become a key market opportunity, but Big Pharma is poorly positioned to take advantage. Having all but abandoned antibiotic drug development at least a decade ago to smaller companies able to take on the risk, major drugmakers now look to those firms as a resource to revive their pipelines. But there may not be much to choose from.
Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline
Antibiotic resistance has become a key market opportunity, but Big Pharma is poorly positioned to take advantage. Having all but abandoned antibiotic drug development at least a decade ago to smaller companies able to take on the risk, major drugmakers now look to those firms as a resource to revive their pipelines. But there may not be much to choose from.
UK Biotech Proximagen Raises Record $80 Million ‘Asset Acquisition’ Fund
In one of the U.K.’s largest fundraisings, Proximagen avoids paying a discount to its share price. Proceeds will buy CNS pipeline assets.